prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-03. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
=== Awards received in the 1990s === Keene P. Dimick Award in Chromatography, Third International Symposium on Supercritical Fluid Chromatography Award for Pioneering Work in the Development of SFC; Marcel J.E. Golay Award and Medal, International Symposium on Capillary Chromatography; American Chemical Society Award in Separation Science and Technology; American Chemical Society Exceptional Achievement Award as a Capillary Gas Chromatography Short Course Instructor; R&D 100 Award for technologically significant new product: -PAGE Polyacrylamide Gel-filled Capillaries for Capillary Electrophoresis”; Jan E. Purkynje Memorial Medal of the Czech Academy of Sciences; R&D Magazine Scientist of the Year Award; M.S. Tswett Memorial Medal of the Russian Academy of Sciences; A.J.P. Martin Gold Medal of the Chromatographic Society of Great Britain; Theophilus Redwood Award, The Royal Society of Chemistry, Great Britain; Distinguished Teaching and Mentoring Award of the University Graduate School, Indiana University; Elected as a Foreign Member of the Royal Society of Sciences (Sweden); College of Arts & Sciences Distinguished Faculty Award, Indiana University.
In published reports by other authors, 2C-B has been claimed to produce effects including visual, auditory, and tactile perceptual changes, closed-eye imagery, LSD-like visuals such as colors and geometric shapes, time dilation, MDMA-like stimulant and entactogenic effects, such as being more in touch with emotions, as well as feelings of love, enhanced sociability, and empathy, feelings of peace and well-being, euphoria, a "body high", increased sensitivity to touch, touch feeling pleasurable, and being erotic. The presence of entactogenic effects with 2C-B is said to be unique among most psychedelics, along with certain other atypical psychedelics like 5-MeO-DiPT and 5-MeO-MiPT. 2C-B's effects are often described as being milder and more easily managed than other psychedelics. For example, it is said to be less incapacitating or impairing, "non-ego-threatening", not "mentally challenging" or confusing, not leading to an "extreme headspace", and leaving the mind "very clear". In addition, it is said to produce changes in thought and time perception less frequently. Due to its potential for relatively light effects, the drug has been referred to as the "Diet Coke of psychedelics" or as a "beginner psychedelic". Nonetheless, it has been described as quite visual, with the potential for all of the visuals of LSD but without the head space that LSD and psilocybin produce. However, the visuals are dose-dependent, being mild at lower doses and being more substantial and LSD-like at higher doses. 2C-B is often compared to a mixture of LSD and MDMA or a "candyflip".
They met during their first week at NSA, though they appear to be having marital difficulties during season thirteen. In "Day in Court", Jake reveals he is having an affair with a fellow NSA Agent. Bishop is horrified and the two separate, with Bishop going home to Oklahoma to get some distance. She later returns to DC to continue with NCIS and tells Jake that their marriage has been deteriorating quickly since she joined NCIS. Despite him wanting to make things work, she has already decided to file for divorce. She sees Gibbs as a father figure and leans on him. After her divorce, she prefers to stay single for a while. It is revealed in "Enemy Combatant" that Bishop is dating NCIS translator Qasim Naasir, last seen in season twelve. Unfortunately, the relationship ends abruptly when Qasim dies from injuries sustained in an attack by a criminal that the NCIS team had been tracking, leaving Bishop grief-stricken and hellbent on exacting revenge for Qasim's murder. Quinn is extremely concerned about her well-being, especially as she eavesdrops on her asking MI6 officer Clayton Reeves to translate the files Qasim was assigned to assist with the case. It is revealed that Qasim proposed to Bishop a few weeks before he died. She asked him for some time to think, and he agreed. Bishop planned to accept the night he died but never had the chance.
Sources: en.wikipedia.org
Due to the heat and expanse of the Houston area residents spent long drives in their cars, "the music that most appropriately complements that has always been the music of DJ Screw, it's slowed down—and when I say slowed down I mean he would record sessions in his apartment with rappers freestyling over beats and he would make these big mixtapes and then he would actually slow them down even further on his cassette recorder." DJ Screw's invoking lean in his lyrics and his use of slow tempos had caused his style to be characterized "[a]s if the song itself has taken too much codeine promethazine". Rappers far beyond Houston would come to adopt aspects of DJ Screw's unique style, but not before he died of a codeine overdose in 2000.
== Adverse effects == Side effects include sedation, dry mouth, drowsiness, increased appetite and weight gain. Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur.
== Causes == As with other eating disorders, binge eating is considered an "expressive disorder": a disorder that is an expression of deeper psychological problems. People who have binge eating disorder have been found to have higher weight bias internalization, which is characterized by low self-esteem, unhealthy eating patterns, and body dissatisfaction. Binge eating disorder commonly develops as a result of or side effect of depression, as it is common for people to turn to comfort foods when they are feeling down. There was resistance to granting binge eating disorder the status of a fully fledged eating disorder because many perceived binge eating disorder to be caused by individual choices. Previous research has focused on the relationship between body image and eating disorders, and concludes that disordered eating might be linked to rigid dieting practices. In the majority of cases of anorexia, extreme and inflexible restriction of dietary intake leads at some point to the development of binge eating, weight regain, bulimia nervosa, or a mixed form of eating disorder not otherwise specified. When under a strict diet that mimics the effects of starvation, the body may be preparing for a new behavioral pattern, one that involves consuming a large amount of food in a relatively short period of time. Some studies show that BED aggregates in families and could be genetic. However, very few published studies of the genetics of BED exist. Research suggests that environmental factors and the impact of traumatic events can precipitate binge eating disorder.
The CCC separation process can be thought of as occurring in three stages: mixing, settling, and separation of the two phases (although they often occur continuously). Vigorous mixing of the phases is critical in order to maximize the interfacial area between them and enhance mass transfer. The analyte will distribute between the phases according to its partition coefficient which is also called the distribution coefficient, distribution constant, or partition ratio and is represented by P, K, D, Kc, or KD. The partition coefficient for an analyte in a particular biphasic solvent system is independent of the volume of the instrument, flow rate, stationary phase retention volume ratio and the g-force required to immobilize the stationary phase. The degree of stationary phase retention is a crucial parameter. Common factors that influence stationary phase retention are flow rate, solvent composition of the biphasic solvent system, and the g-force. The stationary phase retention is represented by the stationary phase volume retention ratio (Sf) which is the volume of the stationary phase divided by the total volume of the instrument. The settling time is a property of the solvent system and the sample matrix, both of which greatly influence stationary phase retention. To most process chemists, the term "countercurrent" implies two immiscible liquids moving in opposing directions, as typically occurs in large centrifugal extractor units.
Sources: en.wikipedia.org
The South African Rugby Board (SARB) for whites, The South African Rugby Federation (SARF) for "coloureds" i.e. people considered to be of mixed race. The South African Rugby Association (SARA) (originally the South African African Rugby Board) for blacks. There was also the South African Rugby Union (SARU), which was a non-racial body, with a considerable membership. However, only the SARB had any say in international tours, and they alone chose the national team. At the end of the 1970s, the SARB took over the SARF and SARA, but Abdul Abbas, leader of SARU refused to co-operate with the new board until the game was integrated at club level and certain political laws scrapped.
== Pharmacokinetics == Unlike many laxative products, lubiprostone does not show signs of drug tolerance, chemical dependency, or altered serum electrolyte concentration. Minimal distribution of the drug occurs beyond the immediate gastrointestinal tissues. Lubiprostone is rapidly metabolized by reduction/oxidation, mediated by carbonyl reductase. There is no metabolic involvement of the hepatic cytochrome P450 system. The measurable metabolite, M3, exists in very low levels in plasma and makes up less than 10% of the total administered dose. Data indicate that metabolism occurs locally in the stomach and jejunum.
=== Early life === Frederik Dag Arfst Paulsen was born on 30 October 1950 in Stockholm, Sweden, as a Swedish citizen. His father was Frederik Paulsen Sr, the founder of Ferring Pharmaceuticals. Paulsen grew up in Sweden, with his father and his father's second wife, Dr. Eva Wolf Frandsen – one of the founding researchers at Ferring. He attended school in Sweden and then went on to study chemistry at the Christian Albrecht University in Kiel, (Germany) and business administration at Lund University in Sweden. He received his doctoral degree in Demography from Ecole des Hautes Etudes en Sciences Sociales in Paris, France.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.